Clinical Toxicology Pharmacokinetics of 13-Cis-Retinoic Acid Administered Chronically at Low Doses Expected for Cancer Chemoprevention Trials
This work was supported by research grants CA-27502 and CA-17094 from the National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20205. We would like to thank Dr. Thomas Moon for his excellent scientific advice and Susan Leigh for her outstanding dedication in the coordination of collection of biological samples.
KeywordsCholesterol Fatigue Toxicity HPLC Lymphoma
Unable to display preview. Download preview PDF.
- 1.Bollag W: Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumors. Int J Vit Res 40:299–314, 1976.Google Scholar
- 11.Davis TP, Peng Y-M, Goodman GE, and Alberts DS: HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. J of Chromatographic Science 20:511–516, 1982.Google Scholar
- 12.Vane FJ and Bugge CJL: Identification of 4-oxo-13-cis-retinoic acid as the major metabolite of 13-cis-retinoic acid in human blood. Fed Proc 39:757, 1980.Google Scholar
- 13.Metzler CM: Nonlin: a computer program for parameter estimation in non-linear situations. Technical Report 7292/69/7272/005. Kalamazoo, Mich.: UpJohn Co., 1969.Google Scholar